Anna M.
- Country
- Italy
- Department
- U.O.C. Oncologia Medica
Research Overview
- EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
- A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer - GeparPiPPa
Data & Insights
Has run more than one trial at 16 of 155 partner sites.
Specializations
Breast Cancer Research
The investigator specializes in treating hormone receptor-positive (HR+) and HER2-positive breast cancer, with particular emphasis on innovative therapeutic approaches.
- Early-stage breast cancer management
- Neoadjuvant therapy optimization
- Targeted therapy combinations
Their research encompasses endocrine therapy applications and novel targeted treatments.
Precision Medicine
The investigator focuses on biomarker-driven treatment approaches, particularly in relation to PIK3CA mutations and circulating tumor DNA analysis.
- Molecular profiling applications
- Personalized treatment strategies
- Biomarker assessment
Their work integrates targeted therapies with specific genetic markers for optimized treatment outcomes.
Treatment Innovation
The investigator explores novel therapeutic combinations including targeted agents such as PI3K inhibitors and selective estrogen receptor degraders.
- Combination therapy development
- Drug resistance mechanisms
- Treatment pathway optimization
Their research evaluates innovative approaches to enhance treatment effectiveness in breast cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.